Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1875 views | HTML 3146 views | ?
Jiayin An1,*, Xiangdong Pei1,*, Zhenle Zang1, Zheng Zhou1, Jintao Hu1, Xin Zheng1, Yin Zhang1, Jiaojiang He2, Lian Duan3, Rufei Shen3, Weihua Zhang4, Feng Zhu5, Song Li1 and Hui Yang1
1Multidisciplinary Center for Pituitary Adenomas of Chongqing, Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China
2Department of Neurosurgery, Lanzhou General Hospital of Chinese People’s Liberation Army, Lanzhou, China
3Department of Endocrinology, Xinqiao Hospital, Third Military Medical University, Chongqing, China
4Department of Biology and Biochemistry, College of Natural Sciences and Mathematics, University of Houston, Houston, Texas, USA
5Innovative Drug Research Centre, University of Chongqing, Chongqing, China
*These authors have contributed equally to this work
Hui Yang, email: [email protected]
Song Li, email: [email protected]
Keywords: metformin, growth hormone-secreting pituitary adenoma, proliferation, ATF3, STAT3
Received: June 11, 2016 Accepted: February 06, 2017 Published: March 25, 2017
Metformin is an anti-hyperglycemic agent used to treat diabetes, and recent evidence suggests it has antitumor efficacy. Because growth hormone-secreting pituitary adenoma (GH-PA) patients have a high incidence of diabetes frequently treated with metformin, we assessed the antitumor effect of metformin on GH-PA. We found that metformin effectively inhibited proliferation and induced apoptosis in the GH-PA cell line GH3. We detected a decrease in mitochondrial membrane potential (MMP), an increase in expression of pro-apoptotic proteins, and a decrease in expression of an anti-apoptotic protein in metformin-treated GH3 cells, which suggests involvement of the mitochondrial-mediated apoptosis pathway. Inhibition of AMPK, which is activated by metformin, failed to reverse the antiproliferative effect. ATF3 was upregulated by metformin, and its knockdown significantly reduced metformin-induced apoptosis. In addition, GH secretion was inhibited by metformin through suppression of STAT3 activity independently of AMPK. Metformin also significantly suppressed cellular proliferation and GH secretion in primary human GH-PA cells. Metformin also significantly inhibited GH3 cell proliferation and GH secretion in vivo. ATF3 upregulation and p-STAT3 downregulation were confirmed in xenografts. These findings suggest metformin is a potentially promising therapeutic agent for the treatment of GH-PA, particularly in patients with diabetes.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.